A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom ...

The CDC's newly reconstituted Advisory Committee on Immunization Practices (ACIP) voted 5-2 in support of infants younger ...

Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

The CDC's vaccine advisory committee said it will study the childhood immunization schedule in the first meeting featuring HHS Secretary RFK Jr.'s hand-selected members.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization. Skip to content. NOWCAST WLKY News at 10:00pm on MeTV.

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

For babies 8 months and younger born to mothers who did not receive a maternal RSV vaccine, monoclonal antibody shots are available. Monoclonal antibodies are proteins manufactured in a lab and ...